Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative DiseasesPRNewsWire • 02/18/21
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 PatientsPRNewsWire • 01/29/21
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals (RIGL) Stock?Zacks Investment Research • 12/21/20
Rigel Pharma: Useful For Some Patients, But Does Not Impress As An InvestmentSeeking Alpha • 12/08/20
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & ExpositionPRNewsWire • 12/04/20
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune ThrombocytopeniaPRNewsWire • 11/23/20
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic AnemiaPRNewsWire • 11/17/20
Rigel Pharmaceuticals' (RIGL) CEO Raul Rodriguez on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/20
Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with InovaPRNewsWire • 10/09/20
Rigel's stock jumps on start of Phase 2 trial for investigational COVID-19 treatmentMarket Watch • 09/17/20
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with InovaPRNewsWire • 09/17/20
Rigel Pharmaceuticals, Inc. (RIGL) CEO Raul Rodriguez on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business UpdatePRNewsWire • 07/28/20